ATE411995T1 - Inhibitoren der alpha-l-beta-2- integrinvermittelten zelladhäsion - Google Patents

Inhibitoren der alpha-l-beta-2- integrinvermittelten zelladhäsion

Info

Publication number
ATE411995T1
ATE411995T1 AT03737649T AT03737649T ATE411995T1 AT E411995 T1 ATE411995 T1 AT E411995T1 AT 03737649 T AT03737649 T AT 03737649T AT 03737649 T AT03737649 T AT 03737649T AT E411995 T1 ATE411995 T1 AT E411995T1
Authority
AT
Austria
Prior art keywords
integrin
inhibitors
beta
alpha
cell adhesion
Prior art date
Application number
AT03737649T
Other languages
German (de)
English (en)
Inventor
Ila Sircar
Marshall Morningstar
Masatoshi Kakushima
Hidefumi Kaji
Takayuki Kawaguchi
Toshiyuki Kume
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Application granted granted Critical
Publication of ATE411995T1 publication Critical patent/ATE411995T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • AIDS & HIV (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
AT03737649T 2002-02-07 2003-02-06 Inhibitoren der alpha-l-beta-2- integrinvermittelten zelladhäsion ATE411995T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US35430902P 2002-02-07 2002-02-07

Publications (1)

Publication Number Publication Date
ATE411995T1 true ATE411995T1 (de) 2008-11-15

Family

ID=27734354

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03737649T ATE411995T1 (de) 2002-02-07 2003-02-06 Inhibitoren der alpha-l-beta-2- integrinvermittelten zelladhäsion

Country Status (23)

Country Link
US (1) US7375128B2 (cg-RX-API-DMAC7.html)
EP (1) EP1472257B1 (cg-RX-API-DMAC7.html)
JP (1) JP2005517016A (cg-RX-API-DMAC7.html)
KR (1) KR100625379B1 (cg-RX-API-DMAC7.html)
CN (1) CN1301255C (cg-RX-API-DMAC7.html)
AR (1) AR040068A1 (cg-RX-API-DMAC7.html)
AT (1) ATE411995T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003210862B2 (cg-RX-API-DMAC7.html)
BR (1) BR0307521A (cg-RX-API-DMAC7.html)
CA (1) CA2474748A1 (cg-RX-API-DMAC7.html)
CO (1) CO5601028A2 (cg-RX-API-DMAC7.html)
DE (1) DE60324250D1 (cg-RX-API-DMAC7.html)
EC (1) ECSP045222A (cg-RX-API-DMAC7.html)
MX (1) MXPA04007643A (cg-RX-API-DMAC7.html)
MY (1) MY137878A (cg-RX-API-DMAC7.html)
NO (1) NO20043563L (cg-RX-API-DMAC7.html)
NZ (1) NZ534208A (cg-RX-API-DMAC7.html)
PE (1) PE20030899A1 (cg-RX-API-DMAC7.html)
PL (1) PL372328A1 (cg-RX-API-DMAC7.html)
RU (1) RU2315768C2 (cg-RX-API-DMAC7.html)
TW (1) TW200303200A (cg-RX-API-DMAC7.html)
WO (1) WO2003066636A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200405647B (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7405234B2 (en) 2002-05-17 2008-07-29 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
TW200407324A (en) * 2002-05-17 2004-05-16 Bristol Myers Squibb Co Bicyclic modulators of androgen receptor function
EP1567487A4 (en) 2002-11-15 2005-11-16 Bristol Myers Squibb Co OPEN-CHAINED, PROLYL-FROSTED MODULATORS OF ANDROGEN RECEPTOR FUNCTION
US7199125B2 (en) 2003-10-02 2007-04-03 Bristol-Myers Squibb Company Spiro-cyclic compounds useful as anti-inflammatory agents
US7820702B2 (en) 2004-02-04 2010-10-26 Bristol-Myers Squibb Company Sulfonylpyrrolidine modulators of androgen receptor function and method
US7696241B2 (en) 2004-03-04 2010-04-13 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
US7625923B2 (en) 2004-03-04 2009-12-01 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
PE20070707A1 (es) * 2005-10-06 2007-08-20 Novartis Ag Compuestos de tetrahidro-pirrolizinona como inhibidores de lfa-1
CN101638429B (zh) * 2009-08-28 2012-01-25 南方医科大学 一种特异性识别细胞表面整合素α3β1的小分子肽
US8497288B2 (en) * 2011-05-09 2013-07-30 Hoffmann-La Roche Inc. Hexahydropyrroloimidazolone compounds
EP3969066B1 (en) * 2019-05-16 2025-08-20 Dispensing Dynamics International, Inc. Fragrance dispenser

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3643748A1 (de) 1986-12-20 1988-06-30 Hoechst Ag Bicylische imide, verfahren zu ihrer herstellung sowie ihre verwendung im pflanzenschutz
DE19622489A1 (de) * 1996-06-05 1997-12-11 Hoechst Ag Salze des 3-(2-(4-(4-(Amino-imino-methyl)-phenyl)-4- methyl-2,5-dioxo-imidazolidin-1-yl)-acetylamino)-3- phenyl-propionsäure-ethylesters
PL336580A1 (en) 1997-03-03 2000-07-03 Boehringer Ingelheim Pharma Fine-molecular compounds useful in treating inflammatory diseases
US6214834B1 (en) * 1997-03-28 2001-04-10 Dupont Pharmaceuticals Company Integrin inhibitor prodrugs
WO1998058947A1 (en) 1997-06-25 1998-12-30 Pfizer Inc. Dipeptide derivatives as growth hormone secretagogues
NZ518369A (en) 1999-10-20 2003-09-26 Tanabe Seiyaku Co 1,3 or 1,8-Diazabicyclo octane or nonane derivatives or tricyclic derivatives useful as inhibitors of alphaL-beta2 mediated cell adhesion
AU6489201A (en) * 2000-05-23 2001-12-03 Histatek Llc Modulaton of alpha-6 integrin-mediated responses

Also Published As

Publication number Publication date
PE20030899A1 (es) 2003-10-25
AU2003210862A1 (en) 2003-09-02
BR0307521A (pt) 2004-12-28
AU2003210862B2 (en) 2006-10-26
MXPA04007643A (es) 2005-06-08
DE60324250D1 (de) 2008-12-04
KR20040091625A (ko) 2004-10-28
MY137878A (en) 2009-03-31
CN1301255C (zh) 2007-02-21
NZ534208A (en) 2005-12-23
CO5601028A2 (es) 2006-01-31
NO20043563L (no) 2004-11-01
CA2474748A1 (en) 2003-08-14
AR040068A1 (es) 2005-03-16
WO2003066636A1 (en) 2003-08-14
EP1472257B1 (en) 2008-10-22
TW200303200A (en) 2003-09-01
US20050171174A1 (en) 2005-08-04
PL372328A1 (en) 2005-07-11
US7375128B2 (en) 2008-05-20
RU2004123219A (ru) 2006-02-10
KR100625379B1 (ko) 2006-09-20
RU2315768C2 (ru) 2008-01-27
ZA200405647B (en) 2005-07-15
CN1628116A (zh) 2005-06-15
JP2005517016A (ja) 2005-06-09
EP1472257A1 (en) 2004-11-03
ECSP045222A (es) 2006-04-19

Similar Documents

Publication Publication Date Title
DK1501508T3 (da) Inhibitorer af histondeatylase
DK1315694T3 (da) Inhibitorer af alpha-4-medieret celleadhæsion
ATE521592T1 (de) Histone-deacetylase-inhibitoren
NO20043642L (no) Heterocykiske tripeptider som hepatitt C inhibitorer
DK1505963T3 (da) Hepatitis C-inhibitorer
DE60317564D1 (de) Hemmung von entzündungen unter verwendungvon alpha-7-rezeptor verbindenden cholinergen agonisten
DE60306904D1 (de) Selektive dipeptidische inhibitoren von kallikrein
DK1562589T3 (da) Diaminotriazoler der er nyttige som inhibitorer af proteinkinaser
ATE557005T1 (de) Heterocyclo-hemmer der kaliumkanalfunktion
EP1499336A4 (en) PROTEASE INHIBITORS
EP1474093A4 (en) Granzyme B INHIBITORS
EP1549316A4 (en) HAMMER OF TFGbeta
EP1660436A4 (en) cathepsin inhibitors
AU2003211093A8 (en) Inhibitors of rgs proteins
ATE402700T1 (de) Glycinamid-derivate als raf-kinase-hemmer
NO20034955L (no) Korrosjonsinhibitor
ATE411995T1 (de) Inhibitoren der alpha-l-beta-2- integrinvermittelten zelladhäsion
ATA92002A (de) Oberflächenschutz für lackierte flächen
DE60316425D1 (de) NF-kappaB-INHIBITOREN
FI20020317A7 (fi) Uudet tärkkelyspohjaiset liimat
NO20043610L (no) Fenylpyrimidinaminer som IgE inhibitorer
DE60326035D1 (de) Dipyridodiazepinone als inhibitoren der reversen transkriptase
SE0203540D0 (sv) Use of an inhibilor or antagonist against lissue factor
UA6562S (uk) Комплект етикеток
UA6687S (uk) Комплект етикеток

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties